Background. The potential reservoirs of leishmaniasis in South Asia include relapsed cases of visceral leishmaniasis (VL), patients with post-kala-azar dermal leishmaniasis (PKDL), and an asymptomatically infected population. Therefore, assessment of cure in terms of parasite clearance, early detection of PKDL, and asymptomatic VL are pivotal for ensuring elimination. This study aimed to monitor the efficacy of miltefosine and liposomal amphotericin B (LAmB) in PKDL based on parasite load.
Leishmaniases caused by digenetic Leishmania parasites comprise a diverse group of neglected tropical diseases of poverty, ranging from a self-limiting cutaneous lesion to the fatal visceral form, and the latter having a dermal sequel called postkala-azar dermal leishmaniasis (PKDL), whose main pockets are South Asia and Sudan [1, 2] . The focused and concerted efforts in implementation of the visceral leishmaniasis (VL) elimination program following launch of the Regional Strategic Framework for VL elimination in 2005 translated into a considerable reduction in the incidence by >75% in the Indian subcontinent [3, 4] . In 2015, 90 of the 456 endemic blocks (20%) in India continued to remain endemic for VL and, more importantly, new foci have emerged in nonendemic regions [5] [6] [7] .
Efforts to prevent infection or interrupt transmission include vector control strategies as also assessing the role of asymptomatic individuals and PKDL. In view of the anthroponotic disease pattern, the parasite-laden papulonodules in PKDL have fueled speculation of its pivotal role in transmission and are the strongest contenders to be the disease reservoir [8] [9] [10] . Accordingly, elimination of PKDL is now an essential component of the VL elimination program currently targeted for 2020 [11] .
Two critical factors that contributed toward reduction of VL cases included (1) early diagnosis by rK-39 strip test [12, 13] and (2) treatment using a single dose of liposomal amphotericin B (LAmB) [14] . However, the management of PKDL remains plagued by lack of a definitive test, as rK39 positivity can be attributed to a past infection with VL. The ideal diagnostic method is demonstration of parasites in smears or culture or by polymerase chain reaction (PCR), which is often logistically not feasible [15] . Furthermore, as PKDL has practically no mortality, patients do not seek treatment and, therefore, conducting clinical trials at least in South Asia is often not feasible. Therefore, an important gap in our knowledge is establishment of the best intervention. Furthermore, as the treatment for PKDL is prolonged, there is always a lurking danger of drug resistance, and is a major concern in view of the limited therapeutic armamentarium [16] .
Miltefosine was approved for VL in India in 2000, and subsequently as a 12-week course for PKDL [17] . However, this was associated with a 15%-20% relapse rate, emphasizing the need for monitoring so as to prevent emergence of drug resistance [18, 19] . Additionally, a treatment regimen for LAmB in PKDL was empirically set at 30 mg/kg body weight for 3 weeks [20] . As studies pertaining to antileishmanial efficacy in PKDL remain limited, this study monitored the efficacy of miltefosine vis-a-vis LAmB using a quantifiable parameter, namely parasite burden, and established that estimation of the parasite load is an effective biomarker for monitoring the disease.
MATERIALS AND METHODS
All reagents were from Sigma-Aldrich (St Louis, Missouri) except rK39 immunochromatographic test strips (InBios International, Seattle, Washington), QIAmp DNA Mini Kit (Qiagen, Hilden, Germany), and SYBR Green Quantitative PCR (qPCR) Master Mix (Applied Biosystems, Grand Island, New York).
Study Population
Patients clinically diagnosed with PKDL (n = 184) were recruited from the Dermatology outpatient departments of the School of Tropical Medicine/Calcutta Medical College/ Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, or from active field surveys conducted in endemic districts of West Bengal (Malda, Dakshin Dinajpur, Murshidabad, and Birbhum) by a camp approach, wherein a house-to-house survey was conducted by first-line health workers (Kala-azar Technical Supervisors) using standard case definitions and defined risk factors, for example, living in an endemic area and having an epidemiological link (past history of VL). These suspected cases were examined at medical camps. Cases with hypopigmented macules were considered as macular PKDL, whereas an assortment of papules, nodules, macules, and/or plaques was termed as polymorphic PKDL [21] . The diagnosis of PKDL was confirmed by the rK39 strip test from blood and internal transcribed spacer-1 (ITS1) [22] . None suffered from any coinfection or preexisting disease, and pregnant women were excluded. The study received approval from the institutional ethics committees, and all patients or their legally accepted representative provided informed written consent.
After confirmation by ITS-1 PCR, cases were randomly allocated to receive miltefosine (50 mg orally twice daily for 12 weeks, n = 84) or LAmB (5 mg/kg body weight intravenously, twice weekly for 3 weeks, n = 98) as per recommended guidelines [23] (Figure 1 ). The dropout rate was high and 108 patients could be monitored at the end of treatment with miltefosine (n = 38) or LAmB (n = 70). Peripheral blood and a 4-mm skin biopsy were collected at 3 time pointsnamely, disease presentation, on completion of treatment, and 6 months later. The clinical outcome was assessed by a dermatologist and they were considered cured based on total regression of papules/nodules, no new lesion(s), and considerable regression of macular lesions. 
Diagnosis by Internal Transcribed Spacer-1 Polymerase Chain Reaction
DNA extraction was performed according to the manufacturer's instructions from a skin biopsy collected in phosphate-buffered saline (20 mM, pH 7.4), excised into small pieces, and DNA eluted in 50 µL of DNA elution buffer. PCR was performed using Leishmania-specific primers LITSR (5′-CTGGATCATTTTCCGATG-3′) and L5.8S (5′-TGATACCACTTATCGCACTT-3′) using Red Taq polymerase in a Master cycler (Eppendorf, Hamburg, Germany) [22] . The PCR products were visualized by agarose gel electrophoresis (2.0%) and analyzed in G-BOX gel doc (Syngene, Cambridge, United Kingdom) using Gene Tools (version 4.01.04) software. DNA from a Leishmania donovani strain MHOM/IN/1983/AG83 served as the positive control, while DNA isolated from the foreskin of healthy individuals (undergoing voluntary circumcision) served as the negative control.
Measurement of Parasite Load by Real-time Polymerase Chain Reaction
For measurement of parasite load, a standard curve was generated by adding a defined number of Leishmania parasites sourced from an L. donovani strain (ranging from 10 to 1 × 10
5
) to blood (180 µL) from a healthy control [19] , and DNA was eluted in 50 μL of DNA elution buffer. Real-time PCR was performed using specific primers for minicircle kinetoplastid DNA (116 bp, forward 5ʹ-CCTATTTTACACCAACCCCCAGT-3ʹand reverse 5ʹ-GGGTAGGGGCGTTCTGCGAAA-3ʹ). DNA (1 µL) was added to a 19-µL reaction mixture containing SYBR Green Master mix and 400 nM of each primer. Negative controls used were DNA from a healthy donor (no amplification), and a reaction mixture with water instead of template DNA (no-template control [NTC] ). The number of parasites was extrapolated from the standard curve and final parasite load stated as the number per microgram genomic DNA [19] . The parasite number when <10 reported a cycle threshold (Ct) value almost equivalent to NTC, and was accorded an arbitrary value of 1.
Statistical Analysis
Data were expressed as median (interquartile range [IQR] ). In cases where 3 groups were compared, nonparametric data were analyzed between groups by the Kruskal-Wallis test followed by Dunn multiple comparison tests; where 2 groups were present, the Mann-Whitney test was used. Correlation was calculated using Spearman rank correlation using GraphPad Prism software version 5.0 (GraphPad Software, La Jolla, California); P < .05 was considered significant.
RESULTS

Study Population
The study included 184 patients diagnosed with PKDL, sourced either by passive surveillance from outpatient departments of medical colleges in Kolkata (n = 54, 2007-2016) or active field surveys in hyperendemic districts of West Bengal (n = 130, 2015-2017). In the passive surveillance group, there was a male preponderance and lesions were predominantly polymorphic (Table 1) . However, by active surveillance, there was no gender bias and the proportion of macular and polymorphic cases was comparable ( Table 1) . Irrespective of the mode of recruitment, the disease duration was comparable. However, in the passive surveillance group, patients sought treatment much later vis-avis enrollment following door-to-door detection (Table 1) .
Upon initial rK39 positivity, the ITS-1 PCR was performed and, when positive (n = 184), the parasite burden was quantified by qPCR in macular (n = 91) and polymorphic (n = 93) PKDL. Their median at disease presentation was 5229 (IQR, 896-50 898). On a lesional basis, the median parasite load in the macular variant was 5.1-fold lower than the polymorphic variant, being 3665 (IQR, 615-21 528) vs 18 620 (IQR, 1266-93 934) (P < .01; Figure 2A ). The Ct value of healthy controls was comparable with the NTC (range, [33] [34] [35] [36] . No correlation was obtained between parasite number and clinical features of PKDL (in terms of disease duration or lag period between cure from VL and onset of PKDL). To examine whether the parasite burden differed depending on the type of lesion, skin biopsies were obtained from 2-3 sites in 3 patients with polymorphic PKDL (ie, macular, papular, and nodular lesions). Irrespective of the anatomical site or type of lesion, the parasite number per microgram gDNA was comparable, as in the first patient, the number was 160 727 and 229 090 from a nodule and papule, respectively. In the second case, it was 157 333, 145 000, and 96 341 from a macule, nodule, and papule, respectively, whereas in the third case, it was 967 826 and 785 714 from a macule and nodule, respectively.
Monitoring of Treatment by Internal Transcribed Spacer-1 Polymerase Chain Reaction
Following ITS-1 PCR positivity, patients were randomly allocated to receive miltefosine or LAmB. In the miltefosine-treated group (n = 38), the ratio of macular to polymorphic lesions was 1:1.23, whereas in 70 patients treated with LAmB, the ratio was 1:1.06 Table 1 ( Figure 1 ). Six months later, cases who received miltefosine (n = 24, macular:polymorphic being 1:1.66) or LAmB (n = 38, macular:polymorphic being 0.8:1) reported to the hospital (Figure 1) . Irrespective of the lesional variant, the repeat ITS-1 PCR at the end of treatment with miltefosine showed no product, whereas following treatment with LAmB, a product was consistently obtained. Cases who returned at any time point 6 months later were examined; patients who received miltefosine demonstrated no ITS-1 PCR product, whereas with LAmB, a product was always obtained.
Monitoring of Treatment by Measurement of Parasite Load in Macular and Polymorphic Variants
Treatment with miltefosine translated into a dramatic parasite clearance as the median parasite load irrespective of the lesion type decreased to 1 (IQR, 1-10) and 1 (IQR, 1-1), in macular and polymorphic PKDL, respectively ( Figure 2B ). Importantly, 6 months later, the number of parasites remained negligible, being 1 (IQR, 1-1), Figure 2B . With LAmB, in macular PKDL (n = 34), treatment decreased the parasite number by 1.72-fold to 2128 (IQR, 544-5763), whereas in the polymorphic variant (n = 36), it decreased significantly by 7.4-fold to 2541 (650-9073) (P < .01; Figure 2C ). Patients who reported 6 months later (n = 38) demonstrated a resurgence of parasite load, as the numbers increased by 2.8-fold in macular lesions to 5882 (IQR, 618-46 686), and in the polymorphic variant by 2.1-fold to 5447 (IQR, 2728-8328) ( Figure 2C ).
Longitudinal Monitoring of Parasite Load Following Treatment With Miltefosine or LAmB
In 19 cases that received miltefosine, the parasite load was serially monitored on completion of treatment and 6 months later. At presentation, their parasite load of 36 500 (IQR, 963-197 362) decreased significantly with treatment to 1 (IQR, 1-1) (P < .001; Figure 3A ). Importantly, this decrease was sustained for at least 6 months as the parasite load remained negligible (1 [IQR, 1-1]) (P < .001; Figure 3A ). This correlated with clinical features as total disappearance of dermal lesions was evident ( Figure 3C, a-c) .
Similarly the parasite burden was serially monitored in 31 patients who received LAmB. During active disease, the parasite load was 33 257 (IQR, 3138-160 727), which decreased by 15.6-fold at the end of treatment to 2128 (IQR, 731-9172) (P < .01; Figure 3B ). In 11 patients who could be monitored 6 months later, the parasite load increased dramatically by 3.6-fold to 7714 (IQR, 3390-1.9 × 10 6 ) (P < .05; Figure 3B ) and reflected in the persistence of their clinical features ( Figure 3C, d-f ).
DISCUSSION
The poorest segment of the endemic population are afflicted by PKDL, and coupled with the negligible mortality of the disease, these individuals tend to not seek treatment or even default treatment [24] . They also refused to provide a skin biopsy, which collectively accounted for the high dropout rate (Figure 1) . With VL/kala-azar becoming a notifiable disease in 2015, active surveillance was undertaken, and unraveled a huge disease burden (Table 1) , thus comprising the largest study in PKDL where the parasite load was quantified (Figures 1 and  2A) . A notable difference that emerged following active surveillance was the considerable decrease in the median disease duration/patient delay to 1 year (Table 1) vis-a-vis previous studies that reported 5 and 3 years, respectively [18, 25] . This highlighted that decreasing the uncovered duration of infectiousness would definitely facilitate the elimination program.
Epidemiological studies with PKDL from Sudan [26] and Bangladesh [8, 27] have not reported a gender bias, whereas studies from India have consistently reported a male preponderance, attributed to males being accorded preferential access to treatment [18, [28] [29] [30] [31] . However, active surveillance identified a substantially higher proportion of females, suggesting there is no gender bias in PKDL (Table 1 ). This study also detected a higher proportion of macular PKDL (Table 1) , which was in contrast to several studies that have reported an overwhelming predominance of the polymorphic variant [18, [29] [30] [31] .
Although the most definitive diagnostic approach in PKDL would be parasite detection in skin smears, it has an unacceptably low detection rate ranging from 4% to 58% [26, 32] . In VL, molecular monitoring of parasites has been effective in detecting asymptomatic VL [33] and in monitoring treatment efficacy [34] . However, studies in PKDL remain limited, primarily due to the limited number and logistic limitations for follow-up. The ITS-1 PCR has been successfully employed for detection of parasite DNA [15, 22] but for monitoring treatment effectiveness, qPCR is a more definitive approach [18] . Irrespective of their sourcing via passive or active surveillance, the parasite burden showed a wide IQR from 896 to 50 898, which was comparable with previous reports [35] . The polymorphic variant showed a significantly higher parasite load vis-a-vis the macular/papular variant ( Figure 2A) and corroborated with other studies [15] . Studies have suggested that parasites in dermal lesions are heterogeneously distributed and that site selection may impact on parasite load [36] . However, quantification of parasite load from multiple sites in 3 PKDL patients indicated that the parasite distribution is remarkably consistent, irrespective of the type or location of the lesion.
A major challenge in macular PKDL is that these hypopigmented lesions are indistinguishable from pityriasis versicolor, further confounded by the inability to detect LD bodies [22, 29] . In such cases, detection of parasite DNA remains the best option, and although the parasite load was significantly lower than polymorphic PKDL, a considerable number was detected (Figure 2A ). There is an ongoing debate regarding the role, if any, of macular lesions in disease transmission. This study has provided evidence that macular lesions possibly harbor an adequate number of parasites for sandfly blood meal-based transmission. Furthermore, in a proof-of-concept experiment [10] , the role of PKDL (maculopapular or nodular lesions) in transmission was confirmed as parasites were identified in infected sandflies, thus countering the conventional belief that macular and papular forms pose a lesser threat than nodular PKDL.
Oral miltefosine provided a breakthrough in the treatment of VL [17] and was subsequently recommended in PKDL (50 mg twice daily × 12 weeks) in adults and once daily in children at 2.5 mg/kg body weight and a favorable response emerged [37, 38] . This study combined clinical evaluation with measurement of parasite load as a quantitative parameter of treatment efficacy ( Figure 2B and 2C) . The improved efficacy of miltefosine may be attributed to the shorter duration of disease, owing to earlier case detection through active surveillance. This quantification was particularly relevant in macular cases, wherein their hypopigmented lesions, although reduced, did not completely resolve. As macular PKDL constitutes almost 50% of PKDL (Table 1) , using this objective parameter of ITS-1 PCR or qPCR ( Figure 2B and 2C) has provided definitive insights. Among 38 patients administered miltefosine, irrespective of the lesional variant, all showed an absence of parasite DNA, substantiated with a nondetectable parasite load at the end of treatment ( Figure 2B) . Importantly, patients who reported at least 6 months continued to remain negative ( Figure 2B) . Additionally, the serial monitoring of 19 patients substantiated the potential of miltefosine in clearing parasites ( Figure 3A and 3C) , thus endorsing it to be the drug of choice for PKDL. However, its declining efficacy [18, 19] , along with parasites demonstrating a reduced accumulation of miltefosine and resistance to oxidative stress [39] , is a matter of concern, emphasizing the need for developing improved therapeutic options.
Challenges with miltefosine include its teratogenic potential as also concerns regarding compliance, endorsing that other therapeutic options be available. The resounding success of LAmB in VL [14] justified its use in PKDL, but owing to the number crunch, the dosage was arbitrarily set at 30 mg/ kg body weight over 3 weeks [23] . In 70 PKDL cases treated with LAmB, parasites persisted ( Figure 2C ) and, importantly, remarkable differences appeared in the 2 variants. In the polymorphic variant (n = 36), the parasite numbers decreased substantially, whereas in the macular variant (n = 34), the parasite numbers, although consistently lower, decreased by only 1.7-fold ( Figure 2C , Figure 3B and 3C), suggesting possible differences in host-parasite interactions. Monitoring of parasite kinetics in 31 patients showed a dramatic resurgence of parasites when they reported 6 months later ( Figure 3B ) and was corroborated by persistence of clinical features ( Figure 3C ). The efficacy of amphotericin B was evaluated in 50 cases of PKDL (a total of 30 mg or 60 mg was administered), and both regimens were effective [40] . Although in our study, a comparable amount of amphotericin B (30 mg) was infused in a liposomal formulation, the persistence of parasites suggests that pharmacokinetics of sustained administration of amphotericin B was better than LAmB, and should be explored further. Taken together, the putative contributory factors could be insufficient treatment duration or dosage, patient's condition (immunosuppression), malnutrition, associated diseases, patient's drug metabolism, or drug resistance, although this is unlikely with LAmB.
Leishmaniasis in South Asia has a relatively limited geographical endemicity, an established anthroponotic transmission with humans being the host reservoir, identification of Phlebotomous argentipes as the only vector species, and availability of effective diagnostic tools coupled with effective treatment, making for a winning combination for elimination of VL. This can be augmented with an effective roadmap that should include early case detection of PKDL, its prompt diagnosis and treatment followed by long-term monitoring of parasite clearance. This study has established that such a model can be implemented and endorses the use of a quantifiable approach for potentially decreasing the disease burden of PKDL and in turn achieving the Sustainable Development Goals [41] .
